Michael Urban was named Vice President of Werewolf Therapeutics, Inc., effective February 13, 2026. As of November 14, 2026, Werewolf Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 13, 2026, naming 1 appointment (Form 8-K, February 13, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Werewolf Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Werewolf Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-13. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Werewolf Therapeutics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-02-13 (layoff filings and notices).
Also on the record for Werewolf Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 21, 2026 | Stake report, Schedule 13G, by MOLL PETER | 5.2% of the class | 5%+ stakes | Source |
| July 2, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 4.1% of the class | 5%+ stakes | Source |
| June 26, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 6% of the class | 5%+ stakes | Source |
| June 22, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 7.5% of the class | 5%+ stakes | Source |
| June 15, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 10.6% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13D/A, by RA Capital Management, L.P. | 12.6% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P. | 3.8% of the class | 5%+ stakes | Source |
| May 5, 2026 | Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P. | 5.4% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G/A, by Longwood Fund III GP, LLC | 3.5% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P. | 6.9% of the class | 5%+ stakes | Source |
| December 29, 2025 | Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P. | 8.2% of the class | 5%+ stakes | Source |
| December 3, 2025 | Stake report, Schedule 13D/A, by MPM BioVentures 2014, L.P. | 10% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Werewolf Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Werewolf Therapeutics, Inc. and the records around it.
Werewolf Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
- Layoff notices Feb 2026
- Who owns it
Companies that share a holder
- MPM BioVentures 2014, L.P. also filed stake reports on 1 other company: ENTRADA THERAPEUTICS, INC. (Sep 2026)
- PFM Health Sciences, LP also filed stake reports on 2 other companies: Outset Medical, Inc. (Feb 2026), PMV Pharmaceuticals, Inc. (Aug 2025)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Evommune, Inc. (Nov 2026), Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026)
Watch Werewolf Therapeutics, Inc.
Get an email when Werewolf Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Werewolf Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Werewolf Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Werewolf Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 16 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-13 | In | Vice President | 2026-02-13 | 8-K, 2026-02-13 |
Who leads Werewolf Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Vice President: Michael Urban, appointed, effective 2026-02-13 (filed 2026-02-13).
New leaders reset buying decisions — get the Full Report on Werewolf Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Vice President at Werewolf Therapeutics, Inc., with the record behind each one.
Find candidates like Vice President at Werewolf Therapeutics, Inc.Every change, in the filing's words
Appointed: Michael Urban, Vice President, effective 2026-02-13
On February 12, 2026, the Company appointed Michael Urban, Vice President of Finance and Corporate Controller, as the Company's principal financial officer and principal accounting officer, effective February 13, 2026.
- Departure of Certain Officers As part of the Reduction, on February 9, 2026, the Company and each of Timothy W. Trost, Chief Financial Officer of the Company, and Dr. Randi Isaacs, M.D., Chief Medical Officer of the Company, agreed that Mr. Trost and Dr. Isaacs would resign as Chief Financial Officer and Chief Medical Officer, as applicable, effective February 13, 2026.
- Both Mr. Trost and Dr. Isaacs are entitled to severance benefits in accordance with their employment agreements upon execution of a separation agreement and general release of claims comprising (i) an amount equal to nine months base salary, and (ii) company contributions to the cost of health care continuation under the Consolidated Omnibus Budget Reconciliation Act for a period of nine months.
- In addition, the separation agreements provide that the exercise period for stock options that are outstanding and vested as of the separation date will be extended from three months until the final exercise date, as such term is defined in the applicable option agreement.
Tools for this story
Each opens in a new tab, filled in for Werewolf Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
